What question did this study set out to answer?

Determine the excretion kinetics of cypermethrin and alphacypermethrin metabolites in human urine following oral and dermal exposures to assess their suitability for biomonitoring.

January 1, 1988Xenobiotica

Human dose-excretion studies with pyrethroid insecticides cypermethrin and alphacypermethrin: Relevance for biological monitoring

View Full Paper

Ask AI

Bookmark

Authors

CEC. V. EadsforthShell (United States)PBPeter C. BragtMinistry of Health Welfare and Sport NSN J van SittertLeiden University

Discussion

Member takes

Implication

Experimental dose-excretion study reveals rapid oral metabolite elimination but minimal dermal absorption of cypermethrin in human volunteers, highlighting constraints for biological monitoring.

Key Points

Determine the excretion kinetics of cypermethrin and alphacypermethrin metabolites in human urine following oral and dermal exposures to assess their suitability for biomonitoring.
Administered single oral doses (0.25 mg, 0.50 mg, 0.75 mg) and 5-day repeated oral doses of alphacypermethrin to healthy volunteers (n=2 per dose level).
Tested 5-day repeated oral cypermethrin doses (0.25 mg, 0.75 mg, 1.5 mg) and a single dermal forearm dose of 25 mg cypermethrin in volunteers (n=2 per dose level).
Collected and analyzed urine samples for free and conjugated 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid metabolites before and across 24 to 72 hours after dosing.
Following a single oral dose of alphacypermethrin, an average of 43% of the dose was excreted as cyclopropanecarboxylic acid within 24 hours, with 49% excreted in subsequent 24-hour windows during repeated dosing without accumulation.
Repeated oral cypermethrin resulted in no metabolite accumulation, clearing an average of 72% of the trans isomer and 45% of the cis isomer in urine across subsequent 24-hour periods.
Only approximately 0.1% of the 25 mg dermal cypermethrin application appeared in urine as cyclopropanecarboxylic acid over 72 hours.

Cite This Study

Eadsforth et al. (1988) studied this question.

synapsesocial.com/papers/6a9bad730b0288a0688fec2d https://doi.org/10.3109/00498258809041697

View Full Paper

Ask AI

Bookmark

January 1, 1988Xenobiotica

Human dose-excretion studies with pyrethroid insecticides cypermethrin and alphacypermethrin: Relevance for biological monitoring

View Full Paper

Ask AI

Bookmark

Authors

CEC. V. EadsforthShell (United States)PBPeter C. BragtMinistry of Health Welfare and Sport NSN J van SittertLeiden University

Discussion

Member takes

Implication

Experimental dose-excretion study reveals rapid oral metabolite elimination but minimal dermal absorption of cypermethrin in human volunteers, highlighting constraints for biological monitoring.

Key Points

Determine the excretion kinetics of cypermethrin and alphacypermethrin metabolites in human urine following oral and dermal exposures to assess their suitability for biomonitoring.
Administered single oral doses (0.25 mg, 0.50 mg, 0.75 mg) and 5-day repeated oral doses of alphacypermethrin to healthy volunteers (n=2 per dose level).
Tested 5-day repeated oral cypermethrin doses (0.25 mg, 0.75 mg, 1.5 mg) and a single dermal forearm dose of 25 mg cypermethrin in volunteers (n=2 per dose level).
Collected and analyzed urine samples for free and conjugated 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid metabolites before and across 24 to 72 hours after dosing.
Following a single oral dose of alphacypermethrin, an average of 43% of the dose was excreted as cyclopropanecarboxylic acid within 24 hours, with 49% excreted in subsequent 24-hour windows during repeated dosing without accumulation.
Repeated oral cypermethrin resulted in no metabolite accumulation, clearing an average of 72% of the trans isomer and 45% of the cis isomer in urine across subsequent 24-hour periods.
Only approximately 0.1% of the 25 mg dermal cypermethrin application appeared in urine as cyclopropanecarboxylic acid over 72 hours.

Cite This Study

Eadsforth et al. (1988) studied this question.

synapsesocial.com/papers/6a9bad730b0288a0688fec2d https://doi.org/10.3109/00498258809041697

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark